您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > DOTA-NHS-ester
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
DOTA-NHS-ester
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
DOTA-NHS-ester图片
CAS NO:170908-81-3
包装与价格:
包装价格(元)
25mg电议
50mg电议
100mg电议

产品介绍
DOTA-NHS-ester是用于affibody分子的交联剂(linker),可用于小型动物正电子发射断层扫描(PET),单光子发射计算机断层扫描(SPECT)和CT扫描。DOTA-NHS-ester可用于标记放射研究剂或者成像探针以检测肿瘤。
Cas No.170908-81-3
别名1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸1-(2,5-二氧代-1-吡咯烷基)酯
Canonical SMILESO=C(ON1C(CCC1=O)=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2
分子式C20H31N5O10
分子量501.49
溶解度DMSO: 50 mg/mL (99.70 mM)
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors[1].

DOTA-NHS-ester can be used to modify human serum albumin (HSA) to produce DOTA-HSA. And DOTA-HSA is furtherly modified by Sulfo-SMCC to obtain DOTA-HSA-SMCC. DOTA-HSA-SMCC is conjugated to ZHER2:342 and the final product is DOTA-HSA-ZHER2:342[1]. In a cell uptake assay, DOTA-HSA-ZHER2:342 is labeled by 64Cu, 64Cu-DOTA-HSA-ZHER2:342 (0.5-2 hours) slowly accumulates in the SKOV3 cells and reaches 0.71% of the applied activity at 0.5 h and the uptake increased to 1.58% at 2 h[1].

In a microPET images of a mouse bearing SKOV3 tumor, 64Cu-DOTA-HSA-ZHER2:342 is injected to the mouse tail. microPET images of a mouse bearing SKOV3 tumor at 1, 4, 24 and 48 h after tail vein injection.The SKOV3 tumor is visible with a low tumor-to-background contrast at 1 h post-injection (p.i.), but with a very good tumor-to-background contrast at 4 and 24 h p.i.Quantification analysis reveals that the SKOV3 tumor uptake values increases with time and are found to be 5.63%, 9.98%, 14.34% and 14.12% ID/g at 1, 4, 24, and 48 h, respectively[1].

[1]. Hoppmann S, et al. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.Bioconjug Chem. 2011 Mar 16;22(3):413-2